URACIL-2-13C
Synonym(s):2,4(1H,3H)-Pyrimidinedione-2-13C
- CAS NO.:35803-45-3
- Empirical Formula: C4H4N2O2
- Molecular Weight: 113.1
- MDL number: MFCD00084096
- SAFETY DATA SHEET (SDS)
- Update Date: 2026-01-13 11:26:28
What is URACIL-2-13C?
The Uses of URACIL-2-13C
2,?4(1H,?3H)?-?Pyrimidinedione-?2-?13C is a labeled analog of Uracil (U801000). 2,?4(1H,?3H)?-?Pyrimidinedione-?2-?13C is used to identify dihydropyrimidine dehydrogenase deficiency by breath test.
Definition
ChEBI: Uracil-(2-13C) is a pyrimidone.
Properties of URACIL-2-13C
| Melting point: | >300 °C (dec.) (lit.) |
Safety information for URACIL-2-13C
Computed Descriptors for URACIL-2-13C
New Products
Dexamethasone Sodium Phosphate p-Anisaldehyde m-Tolualdehyde 2-Bromobenzaldehyde 4-Fluorobenzaldehyde 1-Propyl-4-piperidone 3-Amino-3-(3-fluorophenyl)propanoic acid Raloxifene EP Impurity D N-Nitroso Nortriptyline Nitroso Irbesartan 2-(p-Tolyl)acetaldehyde Sulfonic acid Impurity 2,2-dibromo-1-cyclopropyl-2-(2-fluorophenyl)ethan-1-one 5-Chloro-2-Methoxy-4-Picoline 2-Amino-6-nitrobenzoic Acid (6-Nitroanthranilic acid) Cis-3,5 Diacetoxy-1-cyclopentene 3-Bromo-2-Methoxy-4-Methylpyridine 2-Amino-5-Chloro-3-Nitro-6-picoline 3-Methoxy-5-methylpyrazin-2-amine Pentachlorobenzonitrile Budesonide Nicotinic acid RAPAMYCIN Alpha CyclodextrinRelated products of tetrahydrofuran







You may like
-
Uracil-2-13C CAS 35803-45-3View Details
35803-45-3 -
12029-98-0 >98%View Details
12029-98-0 -
1177-87-3 Dexamethasone Acetate >98%View Details
1177-87-3 -
Hydrocortisone 50-23-7 >98%View Details
50-23-7 -
106-43-4 Parachlorotoluene >99%View Details
106-43-4 -
Pyrrolidin >98%View Details
123-75-1 -
cis-p-Menth-2,8-diene-1-ol 7212-40-0 >98%View Details
7212-40-0 -
Para Chloro toluene (PCT) 106-43-4 >99%View Details
106-43-4
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.
